Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458955 | 0.86 | DCTPP1 (0.51) | NPBWR1MCHR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL4100810 | 0.82 | UCHL1 (0.49) | NPBWR1MCHR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL38653331 | 0.81 | PIN1 (0.46) | TXNRD1 | |
| SCHEMBL13723877 | 0.81 | NPBWR1 (0.60) | NPBWR1MCHR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL3287293 | 0.80 | DCTPP1 (0.58) | NPBWR1MCHR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL4096910 | 0.79 | ALDH1A1 (0.46) | NPBWR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL19170428 | 0.78 | NPBWR1 (0.52) | NPBWR1MCHR1MAPTNPC1RAB9A | |
| SCHEMBL25045656 | 0.77 | NPBWR1 (0.57) | NPBWR1MCHR1DCTPP1MAPTSMN1; SMN2 | |
| SCHEMBL19170435 | 0.76 | NPBWR1 (0.50) | NPBWR1MCHR1MAPT | |
| SCHEMBL20138946 | 0.76 | NPBWR1 (0.56) | NPBWR1MCHR1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| EP-3119775-B1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3119775-B1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8614206-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-24 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NPBWR1 4260/4885MCHR1 4205/4885DCTPP1 1849/4885 |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NPBWR1 4260/4885MCHR1 4205/4885DCTPP1 1849/4885 |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | NPBWR1 3993/4885MCHR1 4166/4885DCTPP1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.